中国医药“出海”更便捷更安全（大健康观察）

Core Viewpoint - The China-ASEAN Regional Pharmaceutical Trading (Procurement) Platform has successfully completed its first cross-border online transaction, marking a significant step in facilitating Chinese pharmaceutical companies' access to ASEAN and SCO countries [1][2]. Group 1: Platform Overview - The platform is an international service trade and settlement platform for pharmaceuticals, officially launched in January 2025, aimed at enhancing cooperation in medical security and pharmaceutical policies with ASEAN and SCO countries [1]. - It has gathered a substantial amount of pharmaceutical resources, currently listing 781 types of drugs and 1,652 categories of medical consumables and equipment, with 114 domestic leading pharmaceutical companies and 10 international buyers registered [2]. - The platform operates under the principle of "government sets the stage, enterprises perform," providing a comprehensive service that includes information dissemination, transaction matching, cross-border settlement, and policy consultation [1][2]. Group 2: Transaction and Settlement Features - Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the first company to complete a cross-border transaction through the platform, highlighting the platform's role in overcoming barriers such as information asymmetry and complex supply chains [2]. - The platform offers a streamlined transaction process, allowing companies to showcase their products and connect directly with buyers, thus reducing communication costs and market risks [2]. - Lianlian International provides multi-currency cross-border payment services, enhancing the efficiency and security of transactions on the platform [3]. Group 3: Platform Characteristics - The platform is characterized by five features: timeliness, authority, innovation, service orientation, and openness, positioning it as a bridge for Chinese pharmaceuticals to connect with international markets [4]. - It actively supports national diplomatic initiatives and updates relevant medical policies and regulations, ensuring the accuracy and reliability of its information [4]. - The platform aims to provide a full-chain service from product display to logistics, emphasizing the need for efficient resource integration [4]. Group 4: Quality Assurance and Challenges - To ensure the quality and credibility of participating companies, the platform requires compliance with legal production and sales licenses, reliable credit, and complete product information [5]. - Despite initial successes, challenges remain, including standard recognition barriers, geopolitical issues, and competition among domestic companies, which may hinder sustainable growth and brand development [5][6]. Group 5: Future Development Focus - The platform aims to enhance its operational mechanisms, improve transaction matching and settlement efficiency, and promote mutual recognition of pharmaceutical regulations with ASEAN countries [6][7]. - It plans to build a professional terminology database for ASEAN medical and pharmaceutical sectors, leveraging local language resources to support international trade [7]. - The platform also seeks to implement more targeted healthcare projects to improve cross-border medical services in ASEAN countries, particularly in areas like thalassemia treatment [7].